LOGIN  |  REGISTER
Recursion
Amneal Pharmaceuticals

Stryker to announce financial results for its first quarter of fiscal year 2024

April 01, 2024 | Last Trade: US$364.60 7.46 2.09

Portage, Michigan, April 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, April 30, 2024.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s first quarter of fiscal year 2024, that ended March 31, 2024.

Stryker will host a webcast at 4:30pm ET on Tuesday, April 30, to discuss results for its first quarter fiscal year 2024.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after the live call ends.

About Stryker

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB